Path To Prevention (P2P) Therapeutics Platform Trial in Stage 2B Neuronal Alpha-Synuclein Disease: Study Update
Objective: To describe the study design and timeline of the first interventional study in Neuronal α-Synuclein Disease (NSD). Background: P2P is a platform, Phase 2…Baseline NSD-ISS stage predicts long term progression and survival in sporadic PD: 10-year PPMI data analysis
Objective: To analyze long term progression in Neuronal Synuclein Disease (NSD) participants who were originally enrolled in the sporadic Parkinson Disease (sPD) cohort in PPMI…Chronic Sleep Fragmentation Accelerates the Onset of Prodromal Symptoms and Pathology in Parkinson’s Disease Model Mice
Objective: To investigate whether chronic sleep fragmentation accelerates the onset of prodromal symptoms and pathology of Parkinson’s disease (PD) in mice. Background: The prodromal phase…IGF2 Induce Neuroprotection in PD Preclinical Models by Modulation of Immune Response.
Objective: We propose to determine a therapeutic strategy based on adoptive transfer of macrophages reprogrammed for recombinant IGF2 (rIGF2) treatment in PD preclinical model. Background:…Hyposmia is Associated with Positive CSF α-Synuclein Seeding in Normal Pressure Hydrocephalus
Objective: To detect α-synuclein (αSyn) pathology and associated clinical characteristics in patients with idiopathic normal pressure hydrocephalus (iNPH) through cerebrospinal fluid (CSF) αSyn seed amplification…α-Synuclein Seed Amplification Assay Amplification Parameters and Progression in Parkinson’s Disease
Objective: To examine the relationship between the reaction parameters of the cerebrospinal fluid (CSF) αSyn seed amplification assay (αSyn-SAA) to the risk of developing motor…Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson’s Consortium
Objective: To advance the regulatory maturity of drug development tools to support the newly proposed integrated staging of Neuronal Synuclein Disease (NSD-ISS) with focus on…Understanding the neuroprotective mechanism of ilex Paraguariensis (Yerba mate) in a Drosophila melanogaster alpha-synuclein model of Parkinson’s disease
Objective: To investigate behavioral and cellular changes in the brain of a Drosophila melanogaster model of Parkinson’s Disease (PD) exposed to yerba mate [YM] extract.…Development of an AAV-mediated artificial miRNA targeting human alpha-synuclein (α-syn) as a potential gene therapy for Synucleinopathies
Objective: To develop an adeno-associated virus (AAV)-based artificial miRNA (miRNA) system targeting human α-syn. Background: Synucleinopathies such as Parkinson’s disease (PD) and Multiple System Atrophy…Plasma pTau181 and pTau217 Detect Amyloid Co-pathology and Have Specific Cut-offs in Lewy Body Disease
Objective: We assess: 1) if the diagnostic accuracy of plasma pTau181 differs from pTau217 in detecting amyloidosis (Aβ) in people with Lewy body disease (LBD)…
- 1
- 2
- 3
- …
- 51
- Next Page »